Proactiveinvestors recommends
Additional Information
Market: OTCBB
Sector: Pharmaceuticals
EPIC: ACCP
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Access Pharmaceuticals
accesspharma.com/index.shtml

Access Pharmaceuticals (ACCP:  OTCBB) is an emerging specialty pharma company developing and commercializing propriety products for the treatment and supportive care of cancer patients.  MuGard, its FDA approved treatment for oral mucositis, is commercially launched in Europe, and will launch in the US and Asian in 1Q 2010.  ProLindac, which is in pivotal clinical trials, is a new and improved version of Sanofi-Aventis’ Eloxatin, a DACH Platinum chemotherapeutic.  Thiarabine is in human trials for the treatment of leukemias and lymphomas.  Lastly, ACCP has collaborations in the areas of oral insulin and oral human growth hormone, using it’s proprietary Cobalamin based oral drug delivery platform.

Full Access Pharmaceuticals profile here
Pdf

Access Pharmaceuticals signs collaborative deal with major pharma company for CobOral insulin

8th Dec 2010, 7:46 pm
Access Pharmaceuticals signs collaborative deal with major pharma company for CobOral insulin

Access Pharmaceuticals (OTCBB: ACCP) said Wednesday it has agreed, with a large undisclosed global pharma company, to test Access' oral insulin formulation for diabetes, based on its CobOral drug delivery technology.

Access said it will provide CobOral insulin to the pharmaceutical company, and it anticipates the completion and delivery of the insulin by the end of the month.

"We continue executing on our broad strategy for unlocking the value of the CobOral and CobaCyte platform technologies through formulation agreements with high-quality partners," said president and CEO of Access Jeffrey Davis. 

"We are confident in our technology's ability to improve the existing standard of administering insulin...we believe that successful testing of the oral insulin product can lead to development programs on additional injectable drugs.”

Access recently announced a deal with another biopharmaceutical company to develop an oral version of the undisclosed company's marketed injectable drug for prostate cancer.

Access has already filed supplementary patents covering the use of both of its drug delivery  platforms, including CobOral and CobaCyte, with many of the top 100 currently-marketed, injectable drugs.   The company said it is continually looking for additional collaborations to turn these injectable drugs into oral formulations.

Access initially focused its CobOral product development program on the oral delivery of insulin and human growth hormone (hGH), two peptides which currently can only be given by injection.

According to the company, a CobOral insulin formulation provided a pharmacological response, or the lowering of blood glucose levels in an animal with diabetes, equivalent to greater than 80% of that achieved by insulin delivered through injection.

Access said that the adaptation of this technology has provided a CobOral HGH formulation that demonstrated "good efficacy", represented by more than 25% improvement in weight gain, when given orally in an animal.

The company's products include MuGard for the management of patients with mucositis and ProLindac, currently in Phase II clinical testing of patients with ovarian cancer, and Thiarabine, a new therapy for certain cancers.

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here